Linezolid Comparable to Clindamycin in Severe or Necrotizing SSTIs, Suggests Study
USA: Researchers have found in a new study that linezolid and clindamycin show similar effectiveness in treating severe or necrotizing skin and soft tissue infections. However, linezolid-based regimens may be associated with a lower risk of acute kidney injury. While clindamycin has traditionally been preferred due to its toxin-inhibiting action, increasing resistance has led to the consideration of linezolid as a viable alternative.
These findings are from a systematic review and meta-analysis published in the Infection journal, led by Ashton Stropes from the Drug Information Center at the University of Missouri, Kansas City School of Pharmacy. The study aimed to compare the clinical outcomes and safety of linezolid-containing regimens with clindamycin combined with anti-gram-positive therapy in patients with severe skin and soft tissue infections (SSTIs), including necrotizing infections.
Necrotizing soft tissue infections are rapidly progressing and potentially fatal conditions often driven by toxin-producing bacteria. Clindamycin has long been favored in such cases due to its ability to suppress toxin production. However, concerns over rising antimicrobial resistance and drug-related adverse effects have prompted interest in alternative agents such as linezolid.
For the analysis, the researchers conducted a comprehensive search of eight medical databases and clinical trial registries up to December 2024. Out of 310 screened articles, four retrospective studies met the inclusion criteria. These studies compared outcomes in patients treated with linezolid-based regimens versus those receiving clindamycin alongside anti-gram-positive antibiotics. Key outcomes assessed included intensive care unit (ICU) length of stay, total hospital stay, mortality, duration of ventilator and vasopressor support, antimicrobial therapy duration, and adverse events.
Key Findings:
- No significant difference was observed between linezolid and clindamycin-based regimens in terms of ICU length of stay.
- Overall, hospital length of stay was also comparable between the two treatment groups.
- Both regimens demonstrated similar effectiveness in managing severe infections.
- Mortality data were limited and did not allow for definitive conclusions.
- No clear differences in mortality were identified between the two treatment approaches.
- Clinical outcomes such as duration of ventilator support were similar across both groups.
- Use of vasopressors was also comparable between the treatment groups.
- Two studies reported a lower incidence of acute kidney injury in patients treated with linezolid.
- This suggests a potential safety advantage of linezolid, particularly in critically ill patients at higher risk of renal complications.
Despite these findings, the authors caution that the evidence should be interpreted carefully. All included studies were retrospective in nature and carried a moderate to high risk of bias. The limited number of studies and variability in study design further restrict the strength of the conclusions.
Overall, the analysis indicates that linezolid may serve as an effective alternative to clindamycin for toxin suppression in severe SSTIs, with a possible benefit in reducing kidney-related adverse events. However, larger, well-designed prospective studies are needed to confirm these findings and guide clinical decision-making.
Reference:
Stropes, A., Lautenschlager, C., Smith, A. et al. Linezolid versus clindamycin for toxin inhibition in severe skin and soft tissue infections: a systematic review and meta-analysis. Infection (2026). https://doi.org/10.1007/s15010-025-02722-6
Next Story